Edurant rilpivirine: Additional Phase III data

Pooled data from 1,368 patients in double-blind, international Phase III ECHO and THRIVE trials showed that 25 mg oral Edurant was non-inferior to Sustiva efavirenz in the proportion of patients who achieved HIV RNA levels <50 copies/mL at week 96 (78% for both). Additionally, the rate of virologic failure at week 96 was 14% for Edurant vs. 8% for Sustiva. Data were presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome. J&J previously reported that Edurant met the primary endpoint in both trials of non-inferiority to Sustiva in the proportion of patients achieving HIV RNA levels <50 copies/mL at week 48 (see BioCentury, April 26, 2010). ...